Direkt zum Inhalt
Merck
  • [Immunomodulation in patients with cavernous kidney tuberculosis using piperazine adipinate and amniocene].

[Immunomodulation in patients with cavernous kidney tuberculosis using piperazine adipinate and amniocene].

Problemy tuberkuleza (1991-01-01)
Iu I Kozin, V I Cherniavskii
ZUSAMMENFASSUNG

Findings of a complex immunologic examination of 138 patients with active cavernous tuberculosis of the kidneys concurrent with secondary immunodeficiency are presented. Biostimulators and immunomodulating drugs were administered as conservative treatment in this case. Changes in cellular and humoral immunity indices as well as those of the mononuclear-phagocyte system before and after treatment were traced in the groups of patients receiving biogenic stimulators (such, as aloe extract, vitreous body, plasmol, Fibs) and immunoregulating drugs (like piperazine adipinate and injected amniocene). It was found that the biogenic stimulators fail to have a pronounced effect on the immunologic indices. The inclusion of piperazine adipinate and injected amniocene into a complex of antibiotic and chemotherapy brings about a significant improvement of the cellular immunity indices and the mononuclear-phagocyte system function which are inhibited to a greater extent in patients with active destructive nephrophthisis. A recommended use of piperazine adipinate and amniocene as adjuncts to a complex treatment has been proved in patients of this category by means of clinicoimmunologic correlations.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Piperazinadipat, European Pharmacopoeia (EP) Reference Standard